scholarly journals Impact of Catheter Ablation on Quality of Life and Healthcare Utilisation

2021 ◽  
Vol 10 (4) ◽  
pp. 258-261
Author(s):  
Sanghamitra Mohanty ◽  
Andrea Natale
Keyword(s):  
Quality Of Life ◽  
Catheter Ablation ◽  
Healthcare Utilisation ◽  
Substantial Improvement ◽  
Resource Utilisation ◽  
Emergency Room Visits ◽  
Healthcare Resource Utilisation ◽  
Cardiovascular Comorbidities ◽  
Very High

Impairment of quality of life (QoL) is a well-known complication of AF. Because of the association of AF with older age and many other cardiovascular comorbidities, there are multiple factors that could influence QoL score even after successful AF intervention. However, substantial improvement in QoL has been reported following catheter ablation for AF regardless of ablation outcomes. In terms of healthcare resource utilisation, the expenses associated with AF are very high because of the hospitalisations for AF-related thromboembolic complications, aggravation of heart failure, AF interventions, and emergency room visits for incessant arrhythmia episodes, and they represent a large economic burden worldwide. Several trials have shown a drastic reduction in healthcare costs following successful AF ablation. In this review, the authors discuss this evidence systematically.

The use of onabotulinumtoxin A in migraine: mechanism of action, efficacy, safety and tolerability

2021 ◽  
Vol 10 (3) ◽  
pp. 98-103
Author(s):  
Gemma Fromage
Keyword(s):  
Quality Of Life ◽  
Episodic Migraine ◽  
Lifestyle Changes ◽  
Resource Utilisation ◽  
Pharmacological Management ◽  
Healthcare Resource Utilisation ◽  
Onabotulinumtoxin A ◽  
Co Morbidity ◽  
The Impact

Migraine is a common, yet disabling, neurological disorder that is characterised by recurrent attacks of headache lasting 4–72 hours at a time. Headaches may also present with associated symptoms, such as nausea, vomiting, photophobia and/or phonophobia. There is a distinction between episodic migraine (EM) and chronic migraine (CM). Classed as a distinct clinical entity, patients with CM suffer from more headache days, increased headache disability, reduced health-related quality of life and greater co-morbidity than those with EM. CM is also considered a greater socioeconomic burden and associated with higher healthcare resource utilisation compared to EM. The main goal in CM treatment is to reduce the impact of migraine on the patient's life. Treatments combine lifestyle changes, trigger management and pharmacological management based on two aims: immediate treatment of acute migraine attacks and prophylactic treatment. Onabotulinumtoxin A is the only botulinum toxin licensed for the prevention of headaches in CM patients. The efficacy of injectable onabotulinumtoxin A for headache prevention in adults with CM was evaluated over 1 year in the phase 3 clinical trials of PREEMPT 1 and PREEMPT 2. A longer term study over a period of 2 years took place, and this phase 4 study was known as COMPEL. Good clinical evidence was found that treatment with onabotulinumtoxin A leads to a reduction of monthly headache days, as well as improvement in quality of life, and was both safe and well tolerated.

Sign in / Sign up

Export Citation Format

Share Document